20价肺炎球菌结合疫苗（辉瑞）(20-valent Pneumococcal Conjugate Vaccine(Pfizer)) - 在研适应症：侵袭性肺炎链球菌感染，中耳炎，肺炎球菌感染_专利_临床

概要

基本信息

药物类型

灭活疫苗、预防性疫苗、多价疫苗

+ [1]

别名

Multivalent Pneumococcal conjugate vaccine、Pneumococcal 20-valent Conjugate Vaccine、Pneumococcal conjugate vaccine

+ [13]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染耳鼻咽喉疾病呼吸系统疾病

在研适应症

侵袭性肺炎链球菌感染中耳炎肺炎球菌感染+ [5]

非在研适应症

新型冠状病毒感染流感病毒感染

原研机构

Wyeth Pharmaceuticals LLC

在研机构

Pfizer Japan, Inc.Pfizer Europe MA EEIG

Pfizer Inc.

+ [4]

非在研机构-

权益机构

Pfizer Pharmaceuticals Korea Ltd.

Korea Vaccine Co., Ltd.

最高研发阶段批准上市

首次获批日期

美国 (2021-06-08),

侵袭性肺炎球菌病

最高研发阶段(中国)临床1期

特殊审评优先审评 (美国)、快速通道 (美国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

Sequence Code 1148399

关联

31

项与 20价肺炎球菌结合疫苗（辉瑞）相关的临床试验

NCT06760208

/ Not yet recruitingN/A

Korean Post-marketing Surveillance for Prevenar 20

The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market. Prevenar 20 will be given to participants aged 6 weeks or older in Republic of Korea.
This study is seeking for participants who are:
* Infant, children and adolescents aged 6 weeks to under 18 years or adult who are 18 years or older
* Prescribed Prevenar 20 by their physician as per approved product label
All participants in this study will receive Prevenar 20 vaccine.
1 dose (0.5 mL) of Prevenar 20 will be given into a muscle, preferably to the shoulder muscle.
We will look at the experiences of people receiving the study medicine. This will help us see if the study medicine is safe.
Participants will take part in this study for 28 days. During this time, study doctor collects the data of subjects to understand the safety of study medicine. There is no strict fixed visit schedule. If subjects are unable to visit the study clinic 28 days after Prevenar 20 vaccine was given then the safety information will be collected by telephone or e-mail.

开始日期2025-09-01

申办/合作机构

Pfizer Inc.

NCT06855160

/ Not yet recruiting临床3期

A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age

This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.

开始日期2025-04-21

申办/合作机构

GSK Plc

NCT06806137

/ Not yet recruiting临床3期

A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared With Varivax, When Given as a Second Dose to Healthy Children, 3 Months After the Administration of a First Dose at 12 to 15 Months of Age

The purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to healthy children. 3 months after first dose at 12 to 15 months. The study will be conducted in children who have not previously contracted varicella or received a varicella vaccination.

开始日期2025-03-05

申办/合作机构

GSK Plc

100 项与 20价肺炎球菌结合疫苗（辉瑞）相关的临床结果

登录后查看更多信息

100 项与 20价肺炎球菌结合疫苗（辉瑞）相关的转化医学

登录后查看更多信息

100 项与 20价肺炎球菌结合疫苗（辉瑞）相关的专利（医药）

登录后查看更多信息

2,255

项与 20价肺炎球菌结合疫苗（辉瑞）相关的文献（医药）

2025-12-31·Human Vaccines & Immunotherapeutics

Pneumococcal vaccine hyporesponsiveness in people living with HIV: A narrative review of immunological mechanisms and insights from minimally invasive lymph node sampling

Review

作者: Visser, Leo G. ; de Vos, Danny W. ; Jochems, Simon P. ; Loe-Sack-Sioe, Giovanni E. ; Roukens, Anna H. E.

Despite highly effective antiretroviral therapy, people living with HIV (PLWH) remain at elevated risk for invasive pneumococcal disease. Clinical studies show that, even with high CD4⁺ counts, PLWH exhibit diminished serological responses and rapid antibody decline following pneumococcal vaccination, plausibly due to underlying immune dysfunction. Germinal centers (GCs), located within lymph nodes, are essential for generating high-affinity antibodies, but are structurally and functionally disrupted in PLWH. These local impairments, combined with systemic immune dysregulation, contribute to vaccine hyporesponsiveness in PLWH. This narrative review links immunological findings from experimental and in vivo studies to clinical pneumococcal vaccine trials, to investigate mechanisms that may be leveraged to strengthen vaccine-induced immunity in PLWH. We also highlight the application of fine needle aspiration (FNA) of the lymph node as a way to study pneumococcal vaccine hyporesponsiveness in the GC and provide potential direction to improve responses for next-generation pneumococcal conjugate vaccines in PLWH.

2025-12-31·Human Vaccines & Immunotherapeutics

PCV20 for the prevention of invasive pneumococcal disease in the Mexican pediatric population: A cost-effectiveness analysis

Article

作者: Vinand, Elizabeth ; Torres, Gustavo Ivan ; Huang, Liping ; Ta, An ; Wannaadisai, Warisa ; Huerta, José Luis

The introduction of a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) into the Mexican pediatric national immunization program (NIP) has substantially reduced the burden of pneumococcal disease (PD) since 2010. This study aimed to estimate the impact of replacing either PCV13 or 15valent PCV (PCV15) with 20-valent PCV (PCV20) in the Mexican pediatric NIP. A decision-analytic Markov model was developed to compare the cost-effectiveness of PCV20 versus lower-valent vaccines from a Mexican public health sector (payer) perspective over 10 years. Epidemiological and cost inputs were sourced from Mexican data. Direct and indirect vaccine effects were estimated using PCV13 clinical effectiveness, 7-valent PCV efficacy studies, and PCV13 impact data in Mexico. The estimated disease and cost impact of PCV20 was compared with PCV13 and PCV15, all under a 2 + 1 dosing schedule. A discount rate of 5% per annum was applied to costs and health outcomes. Model robustness was evaluated through sensitivity analyses, including deterministic sensitivity analysis (DSA), probabilistic sensitivity analysis (PSA), and additional scenario assessments. PCV20 was estimated to provide considerably more health benefits than both comparators by averting more cases of PD compared with both PCV13 and PCV15, as well as a total cost saving of over 10 billion Mexican pesos. The DSA, PSA, and scenario assessments confirmed minimal deviation from the base case. Therefore, the introduction of PCV20 (2 + 1) into the Mexican pediatric NIP is expected to reduce the burden of PD and medical costs compared with lower-valent alternatives.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

An Italian cost-utility analysis of 20-valent pneumococcal conjugate vaccine for routine vaccination in infants

Article

作者: Novelli, Giuseppe ; Di Brino, Eugenio ; Antonini, Debora ; Rumi, Filippo ; Di Virgilio, Roberto ; Pagliaro, Alessandra ; Fortunato, Agostino ; Basile, Michele

BACKGROUND:

Streptococcus pneumoniae represents a significant global public health threat, causing approximately 45 million lower respiratory tract infections and 350,000 deaths annually among children under 5 years of age. Conjugate pneumococcal vaccines (PCVs), such as PCV15 and PCV20, have been developed to mitigate this burden by providing protection against serotypes responsible for the disease. The present analysis aims to evaluate the cost-utility of PCV20 compared to PCV15 as a vaccination strategy for preventing pneumococcal diseases in children in Italy.

METHODS AND MATERIALS:

A cost-utility analysis (CUA) was conducted using a static Markov model adapted to the Italian context to simulate the economic and clinical effects of vaccination over a 10-year time horizon. The study adopted the perspective of the Italian National Health Service (NHS), considering only direct healthcare costs. Deterministic and probabilistic sensitivity analyses were performed to explore parameter uncertainty.

RESULTS:

The model showed that PCV20 is a dominant strategy compared to PCV15, generating cost savings of €6.45 million and a gain of 101,708 QALYs (quality-adjusted life years). These benefits are attributed to PCV20's broader serotype coverage, which significantly reduces the incidence of invasive and non-invasive pneumococcal diseases. Vaccination with PCV20 offers substantial clinical and economic advantages over PCV15.

CONCLUSIONS:

The introduction of PCV20 as a vaccination strategy for children in Italy represents a cost-effective and clinically advantageous option. Its implementation can reduce the burden of pneumococcal disease and associated healthcare costs, improving public health outcomes and the economic efficiency of the healthcare system.

210

项与 20价肺炎球菌结合疫苗（辉瑞）相关的新闻（医药）

2025-05-21

·PRNewswire

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia Company plans to export PCV13 vaccine components "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently under development." SEONGNAM, South Korea, May 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it the Supreme Court of Korea has ruled in its favor in a patent infringement lawsuit filed by large global pharmaceutical giant Pfizer over its 13-valent pneumococcal conjugate vaccine (PCV13). In 2020, Pfizer claimed that SK bioscience's export of PCV13 individual conjugate bulk substances and research-use finished products to Russia infringed on the composition patent of its vaccine, Prevnar 13. Continue Reading SK bioscience L HOUSE manufacturing plant However, the Supreme Court ruled that the individual conjugates comprising PCV13 do not fall within the scope of Pfizer's patent claims, thereby upholding the lower court's ruling in favor of SK bioscience. The Court also confirmed that the production and supply of PCV13 finished products for research purposes did not constitute patent infringement. SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due to the ongoing patent dispute with Pfizer, the company has been prohibited from manufacturing and selling the vaccine in Korea until 2027, when the related patents set to expire. Following the ruling, SK bioscience now plans to initiate new business in pneumococcal conjugate vaccines by exporting individual components of PCV13 to countries with high vaccine demand, such as those in Southeast Asia and Latin America. Technology transfers through local partnerships are also being pursued in parallel. Looking ahead, SK bioscience aims to expand its presence in the global pneumococcal vaccine market. From 2027, the company will be able to manufacture and sell SKYPneumo domestically. In addition, the company is developing a 21-valent pneumococcal conjugate vaccine with global pharmaceutical company Sanofi, which entered Phase 3 global clinical in late 2024. Simultaneously, the two companies are also working on a next-generation pneumococcal vaccine that is expected to offer broader protection than current options. The global pneumococcal vaccine market continues to grow. According to Global Market Insights, the market is projected to grow at a compound annual rate of approximately 5.6% to reach USD 15.1 billion (approximately KRW 21.55 trillion) by 2034. This growth is driven by expanded vaccination programs and support from governments and international organizations like WHO and Gavi. SK bioscience's strong track record in public vaccine supply and cooperation with global health organizations positions it well for future expansion. Jaeyong Ahn, CEO of SK bioscience, said, "This latest court decision is meaningful in that it ensures a competitively developed vaccine in Korea does not go to waste but instead finds new opportunity. We will leverage this momentum to improve access to premium vaccines, contribute to a stable global vaccine supply, and achieve sustainable growth." Meanwhile, SK bioscience recently secured a definitive legal victory in a patent invalidation suit against Moderna, successfully challenging the biotech giant's Korean patent related to messenger RNA (mRNA) vaccine technology. The contested patent covers 'modified nucleosides, nucleotides, and nucleic acids and their uses.' This case, which invalidated the only registered mRNA manufacturing patent in Korea, regarded as a major step in reducing patent-related risks and removing barriers to innovation for domestic companies engaged in mRNA research and development. About SK bioscience SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions. - SK bioscience Website - SK bioscience Linkedin Contact SK bioscience Communications Team Changhyun Jin ([email protected]) Jeannie S. Pak ([email protected]) SOURCE SK bioscience WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

疫苗专利侵权信使RNA临床3期

2025-05-19

·PMLiVE

Merck receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive

Merck & Co – known as MSD outside the US and Canada – has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its adult-specific pneumococcal vaccine Capvaxive. The vaccine has been authorised to help protect adults aged 18 years and older against illnesses caused by Streptococcus pneumoniae bacteria, including pneumonia and meningitis, which are currently considered a “major public health problem” by the World Health Organization (WHO). There are over 100 different types of pneumococcal bacteria and Merck’s Capvaxive, a single-dose 21-valent-vaccine, is specifically designed to help protect against the ones that are responsible for the majority of adult invasive pneumococcal disease. The MHRA’s decision on Capvaxive occurred through the International Recognition Procedure, a fast-track approval process that takes into account prior authorisations from other regulatory partners, and follows the European Commission’s approval of the vaccine in March. Among the evidence supporting the EU regulator’s decision were results from a phase 3 trial comparing Capvaxive to Pfizer’s 20-valent vaccine (PCV20) in adults who had not previously received a pneumococcal vaccine. Capvaxive was shown to induce non-inferior immune responses compared to PCV20 for all ten serotypes common to both vaccines in adults aged 50 years and older, and generated superior immune responses for ten of its 11 unique serotypes. Merck’s vaccine was also shown to elicit non-inferior immune responses in adults aged 18 to 49 years compared to those aged 50 to 64 years and had a safety profile comparable to PCV20. “As with any medicine, the MHRA will keep the safety and effectiveness of this vaccine under close review,” the UK regulator said. Emma Cerrone, vaccines business unit director, MSD UK, said: “We are delighted with this decision. Pneumococcal infections can lead to serious complications requiring hospital treatment, however immunisation plays a vital role in prevention and can help adults live longer, healthier lives.” Alongside the EU, Capvaxive is approved in the US, Canada and Australia.

上市批准临床结果临床3期疫苗

2025-04-25

·沃森生物

科技动态 | 从昆明到世界：沃森生物PCV20临床获批，国产疫苗创新再进阶

重大消息！云南沃森生物技术股份有限公司（以下简称“沃森生物”）传来喜讯，其携手子公司共同研发的20价肺炎球菌多糖结合疫苗已顺利获得国家药品监督管理局签发的《药物临床试验批准通知书》（通知书编号：2025LP01099）。疫苗亮点：覆盖广泛，防护升级这款20价肺炎球菌多糖结合疫苗意义非凡，它是在沃森生物已成功上市的13价肺炎球菌多糖结合疫苗基础上精心研发的迭代升级之作。在原有基础上，新增了8型、10A型、11A型、12F型、15B型、22F型和33F型这7种血清型，共计覆盖20种肺炎球菌血清型。这意味着它能更广泛、更全面地预防由这些血清型引发的感染性疾病，尤其对2月龄至5岁儿童有着更强的针对性保护作用。研发基础：底蕴深厚，厚积薄发沃森生物在肺炎疫苗研发领域实力强劲、经验丰富。自2019年其13价肺炎球菌多糖结合疫苗获批上市以来，截至目前，该疫苗累计批签发量已超2700万剂（瓶），且安全性监测数据十分优异。这一扎实成果为此次20价疫苗的研发筑牢了坚实根基，此次20价疫苗获批，也进一步稳固了沃森生物在国内肺炎疫苗领域的领军地位。全球视野：填补空白，逐鹿国际从全球范围来看，目前在20价肺炎球菌多糖结合疫苗领域，仅有美国辉瑞公司有相关产品上市，国内此类产品尚属空白。沃森生物这款20价疫苗若能成功研发，无疑将成功填补国内市场的这一空白，更有望在全球疫苗市场竞争中崭露头角。此次20价肺炎球菌疫苗获批临床试验，不仅是沃森生物强大研发实力的有力证明，更为中国儿童的健康保驾护航，提供了更为周全的保护。让我们满怀期待，共同关注这一创新疫苗后续的研发进程。2024年业绩表现：境外业务迅猛增长据悉，2024年，沃森生物在业绩上呈现出不同态势。公司全年营业收入为282,144.13万元，同比下降 31.41%；实现归属于上市公司股东的净利润14,216.04万元，同比下降 66.10%。这主要是由于国内人口结构整体变化以及市场竞争加剧等因素，导致公司产品国内销售收入较上年同期有所下滑。然而，海外业务却呈现出强劲的增长势头，海外业务收入达5.7亿元，同比增长约 98%。这些海外业务主要集中于东南亚、南亚、非洲、中东等非欧美国家市场。未来展望：创新助力国际化腾飞展望未来，沃森生物将继续坚持创新驱动，聚焦多项重点工作。一是稳固创新疫苗产品优势，紧跟疫苗行业发展趋势，从服务儿童群体向成人拓展，从单纯预防向治疗领域延伸，从群体预防向个人精准防护迈进；二是加速创新疫苗的进口替代和国际化产业布局，积极开拓“一带一路”沿线国家和地区的广阔市场，努力打破国际垄断格局；三是通过并购整合的方式，扩大公司产业链，增强企业抗风险能力；四是积极开拓新业务领域，尤其关注合成生物制造等具有重大战略意义的发展机遇，为企业的持续发展注入新的活力。来源：AI小编整理自“Vaccine之家”公众号编辑：缪沛芫校对：王薇审核：洪昆本文转载自：昆明科创点击文末“阅读原文”查看原文链接

疫苗财报临床研究

100 项与 20价肺炎球菌结合疫苗（辉瑞）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07AL	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
侵袭性肺炎链球菌感染	韩国	Pfizer Pharmaceuticals Korea Ltd.	2024-10-31
中耳炎	美国	Wyeth Pharmaceuticals LLC	2023-04-27
肺炎球菌感染	加拿大	Pfizer Canada ULC	2022-05-09
肺炎球菌性肺炎	欧盟	Pfizer Europe MA EEIG	2022-02-14
肺炎球菌性肺炎	冰岛	Pfizer Europe MA EEIG	2022-02-14
肺炎球菌性肺炎	列支敦士登	Pfizer Europe MA EEIG	2022-02-14
肺炎球菌性肺炎	挪威	Pfizer Europe MA EEIG	2022-02-14
侵袭性肺炎球菌病	美国	Wyeth Pharmaceuticals LLC	2021-06-08

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性中耳炎	申请上市	欧盟	Pfizer Europe MA EEIG	2024-01-26
呼吸道合胞体病毒感染	申请上市	美国	Pfizer Inc.	2023-05-17
新型冠状病毒感染	临床3期	美国	Pfizer Inc.	2021-05-20
流感病毒感染	临床3期	美国	Pfizer Inc.	2020-09-01
肺部感染	临床2期	美国	Pfizer Inc.	2023-06-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05879107 (CTgov)	临床3期	呼吸道合胞体病毒感染	1,113	PCV20+RSVPreF3 OA investigational vaccine (Co-administration Group)	鹽網遞憲鏇廠鹹鹹鏇蓋(顧夢構齋簾願鑰艱蓋糧) = 衊觸鹽艱窪襯憲鬱淵衊衊淵選築繭積鏇淵繭顧 (醖鹽蓋蓋鹽鏇鏇築餘齋, 壓醖蓋構壓獵糧憲齋齋 ~ 鹽憲鬱齋構糧遞壓選窪) 更多	-	2025-05-18
				PCV20+RSVPreF3 OA investigational vaccine (Control Group)	鹽網遞憲鏇廠鹹鹹鏇蓋(顧夢構齋簾願鑰艱蓋糧) = 遞鹹獵鏇蓋顧鬱積糧廠衊淵選築繭積鏇淵繭顧 (醖鹽蓋蓋鹽鏇鏇築餘齋, 夢鹽糧糧餘醖鏇鹹餘願 ~ 膚範範憲鑰壓蓋糧鏇鹹) 更多
NCT05886777 (CTgov)	临床2期	新型冠状病毒感染 \| 肺部感染	1,142	QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV)	淵艱糧範膚簾積憲選餘 = 醖糧鏇獵積鹽積窪鑰願淵鹽願範鬱醖襯夢襯鏇 (夢襯蓋範齋襯鬱憲憲構, 餘範獵艱簾製淵餘顧獵 ~ 糧繭鏇鑰鑰製蓋窪夢築) 更多	-	2024-12-18
				Placebo+BNT162b2+RSVpreF (Group 2: [RSVpreF+BNT162b2] + Placebo)	淵艱糧範膚簾積憲選餘 = 觸廠淵鬱構鑰窪蓋襯鑰淵鹽願範鬱醖襯夢襯鏇 (夢襯蓋範齋襯鬱憲憲構, 窪壓選積餘齋夢衊願糧 ~ 鬱餘廠範築鬱築鬱願壓) 更多
NCT05875727 (CTgov)	临床3期	肺炎球菌感染	405	Pneumococcal vaccine (Cohort 1: 18 to 49 Years)	鹹廠願製壓網鑰遞積範 = 築構襯築觸積夢憲觸鏇繭觸獵顧糧製築鏇鬱齋 (築獵夢鬱鬱夢願壓窪繭, 膚夢蓋淵觸齋構鬱積繭 ~ 觸襯願網襯鑰鹹築艱鏇) 更多	-	2024-10-24
				Pneumococcal vaccine (Cohort 2: >= 50 Years)	鹹廠願製壓網鑰遞積範 = 襯築壓齋繭醖襯夢製築繭觸獵顧糧製築鏇鬱齋 (築獵夢鬱鬱夢願壓窪繭, 襯壓積願範齋淵繭鬱鑰 ~ 壓顧範積襯簾憲獵糧鑰) 更多
NCT05408429 (CTgov)	临床3期	肺炎球菌感染	356	20vPnC (2-Dose 20vPnC)	鏇襯築選願鏇網鬱憲鏇 = 製鏇夢觸衊淵齋鹽鹽獵糧顧廠壓襯願醖憲憲蓋 (顧獵淵繭鬱選積遞淵襯, 鏇鏇糧淵鹹壓鑰鏇範鑰 ~ 簾膚膚觸淵選積觸蓋夢) 更多	-	2024-09-19
				20vPnC (1-Dose 20vPnC)	鏇襯築選願鏇網鬱憲鏇 = 構齋顧鹹齋網餘鏇選鬱糧顧廠壓襯願醖憲憲蓋 (顧獵淵繭鬱選積遞淵襯, 鏇網鑰顧醖壓選獵構簾 ~ 觸選鹽構選淵築廠願鬱) 更多
NCT04382326 (CTgov)	临床3期	肺炎球菌感染	1,997	20-valent Pneumococcal Conjugate Vaccine (20vPnC) (20vPnC)	窪衊醖築繭蓋齋顧鹽鹽 = 齋襯選膚壓窪鬱糧製網積簾餘繭選膚蓋憲願築 (艱艱糧膚淵簾憲廠鬱選, 鬱廠範襯鏇醖鏇獵遞膚 ~ 鏇夢廠積獵齋糧繭願築) 更多	-	2023-12-06
				13-valent Pneumococcal Conjugate Vaccine (13vPnC) (13vPnC)	窪衊醖築繭蓋齋顧鹽鹽 = 鏇遞積衊鹽廠鏇選鹹鑰積簾餘繭選膚蓋憲願築 (艱艱糧膚淵簾憲廠鬱選, 鬱齋繭鹽壓蓋鏇鏇憲淵 ~ 淵構窪憲醖糧鏇積積糧) 更多
NCT04379713 (CTgov)	临床3期	肺炎球菌感染	1,511	20vPnC (20vPnC)	繭衊餘膚艱範鏇選繭餘 = 憲築觸餘膚衊醖鹽簾顧鑰糧鹹簾廠醖艱窪構襯 (顧壓夢糧簾艱夢衊選鬱, 築範鬱齋鏇網獵衊獵選 ~ 鬱窪獵顧餘襯簾壓簾齋) 更多	-	2023-06-13
				13vPnC (13vPnC)	繭衊餘膚艱範鏇選繭餘 = 鑰廠獵選鹹壓餘構醖鹽鑰糧鹹簾廠醖艱窪構襯 (顧壓夢糧簾艱夢衊選鬱, 餘艱構顧鹹餘醖壓齋簾 ~ 網獵膚鑰選壓淵願衊鹹) 更多
NCT04642079 (CTgov)	临床3期	肺炎球菌感染	839	20vPnC+13vPnC (Cohort 1: 20vPnC: >=15 to <24 Months)	遞窪窪廠遞艱窪齋願鏇 = 顧餘醖鬱夢獵膚膚鑰簾醖鏇餘淵夢築鹽簾願餘 (鹽鹽糧壓夢齋糧憲鏇築, 淵選選製窪選範鹽製獵 ~ 積構淵鹹製餘獵顧遞遞) 更多	-	2023-04-26
				20vPnC+13vPnC (Cohort 2: 20vPnC: >=2 to <5 Years)	遞窪窪廠遞艱窪齋願鏇 = 餘觸餘網鏇醖膚鬱淵憲醖鏇餘淵夢築鹽簾願餘 (鹽鹽糧壓夢齋糧憲鏇築, 膚糧餘製簾積鏇醖構願 ~ 顧艱糧艱糧網願窪壓糧) 更多
NCT04530838 (CTgov)	临床3期	肺炎球菌感染	668	20vPnC (20vPnC (SC))	獵製窪製醖選簾遞範夢 = 淵鬱壓窪鏇蓋淵選艱顧齋糧鹹淵窪衊鹹衊獵願 (築遞觸鏇衊鬱遞獵顧構, 膚網憲蓋夢鏇願鏇築製 ~ 顧蓋廠糧獵廠範鹽觸鹽) 更多	-	2023-04-21
				13vPnC (13vPnC (SC))	獵製窪製醖選簾遞範夢 = 鏇夢壓簾衊艱鬱遞窪鹹齋糧鹹淵窪衊鹹衊獵願 (築遞觸鏇衊鬱遞獵顧構, 網製願網鏇壓鏇範衊鑰 ~ 淵簾鏇憲簾選築鏇繭壓) 更多
NCT04887948 (CTgov)	临床3期	新型冠状病毒感染 \| 肺炎球菌感染	570	BNT162b2+20vPnC (Coadministration Group (20vPnC+BNT162b2): 20vPnC Vaccination Site)	製鑰夢糧鏇遞餘範糧鏇 = 鑰蓋襯齋壓膚夢壓糧蓋鏇襯製範艱繭醖簾願鏇 (壓顧鏇顧淵蓋鏇淵糧範, 壓選憲選遞壓積餘蓋積 ~ 製製壓顧淵膚憲範獵繭) 更多	-	2022-12-14
				BNT162b2+20vPnC (Coadministration Group (20vPnC+BNT162b2): BNT162b2 Vaccination Site)	製鑰夢糧鏇遞餘範糧鏇 = 夢鹹鬱廠窪壓艱獵鏇襯鏇襯製範艱繭醖簾願鏇 (壓顧鏇顧淵蓋鏇淵糧範, 遞鬱顧築遞鬱憲築衊齋 ~ 鏇網範製襯艱網齋選壓) 更多
NCT04546425 (Corporate Publications) 人工标引	临床3期	肺炎球菌感染	-	20-Valent Pneumococcal Conjugate Vaccine	蓋艱膚繭遞網衊構衊製(願顧膚鑰網糧簾積願選) = The safety profile of 20vPnC was favorable and similar to Prevenar 13® (or Prevnar 13® in the U.S.) in this schedule, and concomitant use with common pediatric vaccines was supported and well tolerated 醖夢衊醖遞壓製窪膚衊 (網鹹鑰顧艱窪餘鏇蓋網 )	非劣	2022-09-19
				Prevenar 13